EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

BACKGROUND: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatologists addressing them, a European League Against...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Kostine, Marie, Finckh, Axel, Bingham, Clifton O, Visser, Karen, Leipe, Jan, Schulze-Koops, Hendrik, Choy, Ernest H, Benesova, Karolina, Radstake, Timothy R D J, Cope, Andrew P, Lambotte, Olivier, Gottenberg, Jacques-Eric, Allenbach, Yves, Visser, Marianne, Rusthoven, Cindy, Thomasen, Lone, Jamal, Shahin, Marabelle, Aurélien, Larkin, James, Haanen, John B A G, Calabrese, Leonard H, Mariette, Xavier, Schaeverbeke, Thierry
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Recommendation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7788064/
https://ncbi.nlm.nih.gov/pubmed/32327425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-217139
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados